Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | Avelumab |
| Synonyms | |
| Therapy Description |
Bavencio (avelumab) is a monoclonal antibody binds to human immunosuppressive ligand programmed death-ligand 1 (PD-L1, CD274) and blocks protein signaling, resulting in immune regulation and antitumor immunity (PMID: 26014098). Bavencio (avelumab) is FDA-approved for use in adult and pediatric patients of 12 years or older with metastatic Merkel cell carcinoma, as maintenance therapy in locally advanced or metastatic urothelial carcinoma (UC), in locally advanced or metastatic UC that progressed following chemotherapy, and in combination with axitinib as first-line therapy in advanced renal cell carcinoma (FDA.gov). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Avelumab | Bavencio | MSB0010718C | Immune Checkpoint Inhibitor 151 PD-L1/PD-1 antibody 98 | Bavencio (avelumab) is a monoclonal antibody binds to human immunosuppressive ligand programmed death-ligand 1 (PD-L1, CD274) and blocks protein signaling, resulting in immune regulation and antitumor immunity (PMID: 26014098). Bavencio (avelumab) is FDA-approved for use in adult and pediatric patients of 12 years or older with metastatic Merkel cell carcinoma, as maintenance therapy in locally advanced or metastatic urothelial carcinoma (UC), in locally advanced or metastatic UC that progressed following chemotherapy, and in combination with axitinib as first-line therapy in advanced renal cell carcinoma (FDA.gov). |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 positive | transitional cell carcinoma | sensitive | Avelumab | Phase III | Actionable | In a Phase III trial (JAVELIN Bladder 100), addition of maintenance Bavencio (avelumab) to best supportive care (BSC) significantly improved overall survival compared to BSC alone (not reached vs 17.1 mo, HR=0.56, p=0.0003) in patients with CD274 (PD-L1)-positive advanced urothelial carcinoma (J Clin Oncol 38, (Jun 2020) no. 18_suppl; NCT02603432). | detail... |
| MLH1 negative | endometrial carcinoma | sensitive | Avelumab | Guideline | Actionable | Bavencio (avelumab) is included in guidelines as a second-line or subsequent-line therapy for patients with high microsatellite instability (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent endometrial carcinoma (NCCN.org). | detail... |
| MSH2 negative | endometrial carcinoma | sensitive | Avelumab | Guideline | Actionable | Bavencio (avelumab) is included in guidelines as a second-line or subsequent-line therapy for patients with high microsatellite instability (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent endometrial carcinoma (NCCN.org). | detail... |
| MSH6 negative | endometrial cancer | sensitive | Avelumab | Phase II | Actionable | In a Phase II trial, Bavencio (avelumab) treatment resulted in an objective response rate of 26.7% (4/15, 1 complete response, 3 partial responses) and 6-month progression-free survival rate of 40% (6/15) in patients with mismatch repair deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or persistent endometrial cancer (PMID: 31461377; NCT02912572). | 31461377 |
| MSH6 negative | endometrial cancer | sensitive | Avelumab | Guideline | Actionable | Bavencio (avelumab) is included in guidelines for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial cancer who have failed platinum-based therapy (PMID: 35690222; ESMO.org). | 35690222 detail... |
| PMS2 negative | endometrial cancer | sensitive | Avelumab | Guideline | Actionable | Bavencio (avelumab) is included in guidelines for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial cancer who have failed platinum-based therapy (PMID: 35690222; ESMO.org). | detail... 35690222 |
| PMS2 negative | endometrial cancer | sensitive | Avelumab | Phase II | Actionable | In a Phase II trial, Bavencio (avelumab) treatment resulted in an objective response rate of 26.7% (4/15, 1 complete response, 3 partial responses) and 6-month progression-free survival rate of 40% (6/15) in patients with mismatch repair deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or persistent endometrial cancer (PMID: 31461377; NCT02912572). | 31461377 |
| PMS2 negative | endometrial carcinoma | sensitive | Avelumab | Guideline | Actionable | Bavencio (avelumab) is included in guidelines as a second-line or subsequent-line therapy for patients with high microsatellite instability (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent endometrial carcinoma (NCCN.org). | detail... |
| MSH6 negative | endometrial carcinoma | sensitive | Avelumab | Guideline | Actionable | Bavencio (avelumab) is included in guidelines as a second-line or subsequent-line therapy for patients with high microsatellite instability (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent endometrial carcinoma (NCCN.org). | detail... |
| MLH1 negative | endometrial cancer | sensitive | Avelumab | Phase II | Actionable | In a Phase II trial, Bavencio (avelumab) treatment resulted in an objective response rate of 26.7% (4/15, 1 complete response, 3 partial responses) and 6-month progression-free survival rate of 40% (6/15) in patients with mismatch repair deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or persistent endometrial cancer (PMID: 31461377; NCT02912572). | 31461377 |
| MLH1 negative | endometrial cancer | sensitive | Avelumab | Guideline | Actionable | Bavencio (avelumab) is included in guidelines for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial cancer who have failed platinum-based therapy (PMID: 35690222; ESMO.org). | 35690222 detail... |
| MSH2 negative | endometrial cancer | sensitive | Avelumab | Guideline | Actionable | Bavencio (avelumab) is included in guidelines for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR, often defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) endometrial cancer who have failed platinum-based therapy (PMID: 35690222; ESMO.org). | 35690222 detail... |
| MSH2 negative | endometrial cancer | sensitive | Avelumab | Phase II | Actionable | In a Phase II trial, Bavencio (avelumab) treatment resulted in an objective response rate of 26.7% (4/15, 1 complete response, 3 partial responses) and 6-month progression-free survival rate of 40% (6/15) in patients with mismatch repair deficient (dMMR, defined by the loss of MLH1, PMS2, MSH2, or MSH6 expression by IHC) recurrent or persistent endometrial cancer (PMID: 31461377; NCT02912572). | 31461377 |
Filtering
- Case insensitive filtering will display rows where any text in any cell matches the filter term
- Simple literal full or partial string matches
- Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
- Use quotes to match a longer phrase which contains spaces "mtor c1483f"
Sorting
- Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03944941 | Phase II | Avelumab Avelumab + Cetuximab | Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer | Recruiting | USA | 0 |
| NCT04068194 | Phase Ib/II | Avelumab Avelumab + Peposertib | Testing the Combination of New Anti-cancer Drug Nedisertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies | Recruiting | USA | 0 |
| NCT03747419 | Phase II | Avelumab | Avelumab and Radiation in Muscle-Invasive Bladder Cancer | Recruiting | USA | 0 |
| NCT03387098 | Phase Ib/II | GI-4000 Leucovorin Nab-paclitaxel Bevacizumab Avelumab ALT-803 Fluorouracil ETBX-011 Oxaliplatin Aldoxorubicin Capecitabine Cyclophosphamide | QUILT-3.070: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | Unknown status | USA | 0 |
| NCT03244176 | Phase I | Avelumab | Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study (AvR-CHOP) | Active, not recruiting | 1 | |
| NCT03278405 | Phase Ib/II | Avelumab | Avelumab in G3 NEC (NET-001) | Completed | CAN | 0 |
| NCT03056599 | Phase I | Pembrolizumab Avelumab Interferon gamma Olaratumab Trabectedin Nivolumab Gemcitabine Interferon alpha-2b Doxorubicin Atezolizumab Eribulin Ipilimumab Durvalumab Aldesleukin Bortezomib Docetaxel | Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma | Completed | USA | 0 |
| NCT03387111 | Phase Ib/II | Capecitabine Nab-paclitaxel Leucovorin GI-6301 GI-6207 Avelumab ETBX-021 ETBX-051 ETBX-061 Aldoxorubicin Cisplatin Cyclophosphamide Bevacizumab Necitumumab GI-4000 Cetuximab ALT-803 Fluorouracil ETBX-011 | Molecularly Informed Integrated Immunotherapy Combining Innate haNK Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With SCC Who Have Progressed on or After Platinum-based Chemotherapy and Anti- PD-1/ PD-L1 Therapy | Unknown status | USA | 0 |
| NCT01772004 | Phase I | Avelumab | Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor) | Completed | USA | FRA | DEU | BEL | 5 |
| NCT03893903 | Phase I | Avelumab IDH1 R132H peptide vaccine Avelumab + IDH1 R132H peptide vaccine | AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma (AMPLIFY-NEOVAC) | Recruiting | DEU | 0 |
| NCT04322643 | Phase II | Durvalumab Pembrolizumab Avelumab Nivolumab Atezolizumab | Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma | Recruiting | USA | 0 |
| NCT02968940 | Phase II | Avelumab | Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma | Completed | USA | 0 |
| NCT03158883 | Phase I | Avelumab | UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients | Completed | USA | 0 |
| NCT02155647 | Phase II | Avelumab | Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | 2 |
| NCT03135769 | Phase II | Avelumab | Avelumab in Chemo-resistant Gestational Trophoblastic Neoplasias (TROPHIMMUN) | Completed | FRA | 0 |
| NCT03774901 | Phase II | Avelumab | Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma (PULSE) | Recruiting | FRA | 0 |
| NCT03910439 | Phase II | Avelumab | Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma | Terminated | USA | 0 |
| NCT03498196 | Phase Ib/II | Avelumab | A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer | Terminated | USA | 0 |
| NCT03006848 | Phase II | Avelumab | A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma | Active, not recruiting | USA | 0 |
| NCT03260023 | Phase Ib/II | Avelumab Avelumab + Tipapkinogene sovacivec | Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers | Recruiting | USA | FRA | ESP | 0 |
| NCT02603432 | Phase III | Avelumab | A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100) | Active, not recruiting | USA | ITA | FRA | ESP | CAN | BEL | 23 |
| NCT03000179 | Phase II | Avelumab | Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma | Terminated | USA | 0 |
| NCT03047473 | Phase II | Avelumab | Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme (SEJ) | Completed | CAN | 0 |
| NCT02584634 | Phase I | Crizotinib Avelumab Lorlatinib | Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101) | Completed | USA | ESP | 3 |
| NCT04792073 | Phase II | Avelumab | Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma | Recruiting | USA | 0 |
| NCT03136406 | Phase Ib/II | GI-4000 Leucovorin Avelumab Nab-paclitaxel Bevacizumab Cyclophosphamide Capecitabine Oxaliplatin Fluorouracil ETBX-011 ALT-803 | QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | Unknown status | USA | 0 |
| NCT02576574 | Phase III | Gemcitabine Paclitaxel Cisplatin Avelumab Pemetrexed Disodium Carboplatin | Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 35 |
| NCT03288350 | Phase II | Cisplatin + Docetaxel + Fluorouracil Avelumab | mDCF + Avelumab in Resectable Esophago-gastric Adenocarcinoma (EGA) | Recruiting | CAN | 0 |
| NCT03387085 | Phase Ib/II | ETBX-051 Aldoxorubicin ETBX-061 Cisplatin Cyclophosphamide haNK cells GI-4000 Bevacizumab ALT-803 Fluorouracil ETBX-011 Oxaliplatin Capecitabine Leucovorin GI-6301 Nab-paclitaxel Avelumab GI-6207 | QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. | Active, not recruiting | USA | 0 |
| NCT03674424 | Phase II | Avelumab + Gemcitabine + Paclitaxel Avelumab + Cisplatin + Doxorubicin + Methotrexate + Vinblastine Avelumab Avelumab + Cisplatin + Gemcitabine | Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial) (AURA) | Active, not recruiting | FRA | BEL | 0 |
| NCT02603419 | Phase I | Avelumab | Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS) | Terminated | USA | ITA | 1 |
| NCT03312114 | Phase II | Avelumab | Anti—PD-L1 and SAbR for Ovarian Cancer | Terminated | USA | 0 |
| NCT04387084 | Phase I | Durvalumab Pembrolizumab Avelumab Cemiplimab Atezolizumab Nivolumab | Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy | Recruiting | USA | 0 |
| NCT04841148 | Phase II | Hydroxychloroquine Avelumab + Palbociclib Hydroxychloroquine + Palbociclib Avelumab | Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer (PALAVY) | Recruiting | USA | 0 |
| NCT03278379 | Phase II | Avelumab | Avelumab in G2-3 NET (NET-002) | Unknown status | CAN | 0 |
| NCT03815643 | Phase III | Avelumab | Avelumab Program Rollover Study | Active, not recruiting | USA | ITA | FRA | DEU | BEL | 11 |
| NCT02859454 | Phase II | Avelumab | Avelumab for People With Recurrent Respiratory Papillomatosis | Completed | USA | 0 |
| NCT03186326 | Phase II | Aflibercept + Fluorouracil + Irinotecan + Leucovorin Aflibercept + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab Cetuximab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin + Panitumumab Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Avelumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin | Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer (SAMCO) | Active, not recruiting | FRA | 0 |
| NCT03179410 | Phase II | Avelumab | PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer (PICK-NEPC) | Completed | USA | 0 |
| NCT02584829 | Phase Ib/II | IFN-B Avelumab | Localized Radiation Therapy or Recombinant Interferon Beta and MSB0010718C With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma | Terminated | USA | 0 |
| NCT02767063 | Phase Ib/II | Avelumab Pioglitazone | Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW) | Recruiting | FRA | 0 |
| NCT03267836 | Phase I | Avelumab | Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma | Active, not recruiting | USA | 0 |
| NCT03617666 | Phase II | Avelumab | Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study (AVENuE) | Active, not recruiting | 2 | |
| NCT03050554 | Phase Ib/II | Avelumab | Stereotactic Body Radiation Therapy (SBRT) Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC) | Terminated | USA | 0 |
| NCT02625610 | Phase III | Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Avelumab Capecitabine + Oxaliplatin | Avelumab in First-Line Gastric Cancer (JAVELIN Gastric 100) | Completed | USA | ITA | FRA | ESP | DEU | CAN | 11 |
| NCT02912572 | Phase II | Avelumab + Talazoparib Avelumab Avelumab + Axitinib | Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer | Recruiting | USA | 0 |
| NCT02718417 | Phase III | Avelumab Carboplatin + Paclitaxel | Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) | Terminated | USA | ITA | DEU | CAN | 21 |
| NCT05092958 | Phase III | Avelumab + Cabozantinib Avelumab | Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study | Recruiting | USA | 0 |
| NCT03271372 | Phase III | Avelumab | Adjuvant Avelumab in Merkel Cell Cancer (ADAM) | Recruiting | USA | 0 |
| NCT03399552 | Phase Ib/II | Avelumab | Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma | Completed | USA | 0 |
| NCT03719768 | Phase I | Avelumab | Avelumab With Radiotherapy in Patients With Leptomeningeal Disease | Active, not recruiting | USA | 0 |
| NCT03076554 | Phase II | Avelumab | A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy | Recruiting | USA | 0 |
| NCT02875613 | Phase II | Avelumab | Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer | Terminated | USA | 0 |
| NCT03391479 | Phase II | Avelumab | A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy | Recruiting | CAN | 0 |
| NCT03341806 | Phase I | Avelumab | Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma | Completed | USA | 0 |
| NCT02580058 | Phase III | Doxorubicin Avelumab | A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer | Completed | USA | ITA | FRA | ESP | CAN | BEL | AUT | 18 |
| NCT03035630 | Phase II | Avelumab Sunitinib | Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma | Withdrawn | USA | 0 |
| NCT02943317 | Phase I | Defactinib Avelumab | Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer | Terminated | USA | 0 |
| NCT03451825 | Phase Ib/II | Avelumab | Phase I/II Study of Avelumab in Pediatric Cancer Subjects | Completed | USA | CAN | BEL | 2 |
| NCT02395172 | Phase III | Avelumab Docetaxel | Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200) | Completed | USA | ITA | FRA | ESP | BEL | 24 |
| NCT04261855 | Phase Ib/II | Avelumab Avelumab + lutetium Lu 177 dotatate | Targeted Therapy and Avelumab in Merkel Cell Carcinoma (GoTHAM) | Recruiting | 1 | |
| NCT02625623 | Phase III | Avelumab Paclitaxel Irinotecan | Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) | Completed | USA | ITA | FRA | ESP | DEU | BEL | 4 |
| NCT04637594 | Phase III | Durvalumab Nivolumab Atezolizumab Avelumab Pembrolizumab | Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy | Recruiting | USA | 0 |
| NCT04291885 | Phase II | Avelumab | Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma (I-MAT) | Recruiting | 1 | |
| NCT02915523 | Phase Ib/II | Avelumab Avelumab + Entinostat | Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer | Completed | USA | 0 |
| NCT04065555 | Phase I | Avelumab + Subasumstat Cetuximab Cetuximab + Subasumstat Subasumstat Avelumab | Intratumoral Microdosing of TAK-981 in Head and Neck Cancer | Completed | USA | 0 |
| NCT05327530 | Phase II | Avelumab Avelumab + NKTR-255 Avelumab + Sacituzumab govitecan-hziy Avelumab + M6223 | A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley) | Recruiting | USA | ESP | BEL | 2 |
CKB BOOST